Exact Sciences
Exact Sciences Corporation is an American molecular diagnostics and biotechnology company specializing in the development and commercialization of screening tests for early cancer detection, prominently featuring its flagship non-invasive stool DNA screening test for colorectal cancer, Cologuard, alongside oncotype genomic diagnostic assays. The company operates advanced clinical laboratories and biotechnology research facilities, providing precision cancer screening and diagnostic profiling services to healthcare providers and patients globally. Its core business activities encompass molecular diagnostic research, clinical laboratory testing, cancer screening test manufacturing, and commercial healthcare marketing. Revenue is derived primarily from clinical laboratory service fees, direct commercial sales of Cologuard test kits, and oncotype diagnostic assay revenues. Exact Sciences holds a leading market position in non-invasive cancer screening and molecular diagnostics. The company is headquartered in Madison, Wisconsin, United States, and its common stock trades on the Nasdaq Global Select Market.
3 of the funds FundTelligence covers report a position in Exact Sciences.
- Legal name
- Exact Sciences Corp
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 3
- Exposure themes
- Cancer Profiling, Molecular Diagnostics, Precision Medicine & Genomics
Funds holding Exact Sciences
- BGF Next Generation Health Care Fund — BlackRock · 2.98 % (largest positions only, January 2026)
- Schroder ISF Global Convertible Bond — Schroders · 0.23 % (full portfolio disclosed, June 2026)
- Mercer Global Small Cap Equity Fund — Mercer · 0.06 % (full portfolio disclosed, December 2025)